Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib

Michael FreiDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Samuel L. AitkenDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ;Center for Antimicrobial Resistance and Microbial Genomics (CARMiG); UTHealth McGovern Medical School, Houston, TX, USA;

Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Philip ThompsonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

William WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Dimitrios P. KontoyiannisDepartment of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Adam J. DiPippoDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]

http://orcid.org/0000-0002-5986-0190

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

NJ: Research funding to institution from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, and Precision Biosciences for clinical studies in which NJ is a principal investigator, advisory board member and honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, and Precision Biosciences; PT: Research funding to institution from Pharmacyclics, AbbVie, Genentech and AstraZeneca, advisory board member and honoraria from Pharmacyclics, AbbVie, Gilead, Genentech, speaking fees from Janssen; MF, SLA, WW, DPK, AJD: no relevant disclosures.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib

Information for

Open access

Opportunities

Help and information

Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature